ZIMMER BIOMET HOLDINGS INC (NYSE:ZBH) Reveals Intriguing Technical Aspects. Indications Suggest NYSE:ZBH Could Be on the Verge of a Breakout. Here's What You Need to Know.
While the S&P 500 includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including STERIS (NYSE:STE) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Zimmer Biomet (NYSE:ZBH) and the best and worst performers in the surgical equipment & consumables - diversified industry.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how surgical equipment & consumables - diversified stocks fared in Q4, starting with Solventum (NYSE:SOLV).
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including BD (NYSE:BDX) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at CONMED (NYSE:CNMD) and the best and worst performers in the surgical equipment & consumables - diversified industry.
Medical device company Zimmer Biomet (NYSE:ZBH) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.3% year on year to $2.02 billion. Its non-GAAP profit of $2.31 per share was 0.8% above analysts’ consensus estimates.
It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged up 0.3%, while the Dow Jones slipped 0.1% and small caps held steady.
Zimmer Biomet agrees to acquire Paragon 28 for $1.1 billion, with a non-tradeable CVR up to $1 per share. Deal expected to close in first half of 2025.
The robotic-assisted surgery trend is accelerating and Intuitive Surgical continues to lead the pack as its continued to keeps its wide moat since 2000.
Medtronic (MDT) and Zimmer Biomet (ZBH) are emerging as serious contenders in robotic surgery, challenging Intuitive Surgical’s (ISRG) market dominance.
We are looking for value in the Healthcare Sector because we are still in a strong bull market that has been not only one of the longest on record, but also has seen the S&P 500 get to one of its lofty valuations ever.
